<DOC>
	<DOCNO>NCT01107756</DOCNO>
	<brief_summary>Primary Objective : To evaluate incidence severity neutropenia patient treat solid tumour Taxotere® base regimen Granocyte® 34 use primary prophylaxis chemotherapy-induced neutropenia . Secondary Objectives : Haematological : To evaluate incidence severity febrile neutropenia ( without antibiotic ) anaemia patient treat solid tumor treat Taxotere base regimen Granocyte use primary prophylaxis . Non-Haematological : To evaluate incidence severity follow adverse event : asthenia , anorexia , myalgia , nail change oral mucositis patient solid tumour treat Taxotere base regimen ; Granocyte use primary prophylaxis .</brief_summary>
	<brief_title>A Clinical Trial Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor Primary Prophylaxis Chemotherapy-induced Neutropenia , Docetaxel Based Regimen</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion criterion : Patients willing sign inform consent prior entry study , Patients prescribe Taxotere base regimen , Patients yet start first Taxotere treatment , Patients histological diagnosis one follow solid tumour : breast cancer , nonsmall cell lung cancer ( NSCLC ) , ovarian cancer , prostate cancer , gastric cancer head neck cancer . Exclusion criterion : Patients enrol another clinical study , Pregnant and/or breastfeed patient , include woman childbearing potential willing use medically acceptable method contraception , Patients severe liver impairment , Patients severe renal function impairment , Patients know hypersensitivity Granocyte 34 constituent , Patients history severe hypersensitivity reaction Taxotere Polysorbate 80 , Patients baseline neutrophil count &lt; 1500cells/mm3 , Patients drug contraindication use Taxotere , Patients concurrent radiotherapy . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>